Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Emmanuel S AntonarakisSe Hoon ParkJeffrey C GohSang Joon ShinJae Lyun LeeNiven MehraRay S McDermottNúria Sala-GonzalezPeter C FongRichard GreilMargitta RetzJuan Pablo SadePatricio YanezEric Yi-Hsiu HuangStephen D BegbieRustem Airatovich GafanovMaria De SantisEli RosenbaumMichael P KolinskyFelipe ReyKun-Yuan ChiuGuilhem RoubaudGero KramerMakoto SumitomoFrancesco MassariHiroyoshi SuzukiPing QiuJinchun ZhangJeri KimChristian H PoehleinEvan Y YuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.